XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
  Depression
   Antidepressants
  Neuropsychiatry
  Personality Disorders
  Bulimia
  Anxiety
  Substance Abuse
  Suicide
  CFS
  Psychoses
  Child Psychiatry
  Learning-Disabilities
  Psychology
  Forensic Psychiatry
  Mood Disorders
  Sleep Disorders
  Peri-Natal Psychiatry
  Psychotherapy
  Anorexia Nervosa
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04
Systematic Review
The Cochrane Library

Depression Channel
subscribe to Depression newsletter

Latest Research : Psychiatry : Depression

   DISCUSS   |   EMAIL   |   PRINT
Pain generated by damage to the nervous system can be treated with antidepressants
Jul 20, 2005, 15:07, Reviewed by: Dr.

The most convincing evidence was for amitriptyline in doses up to 150mg per day, which achieved at least moderate pain relief. It was difficult to assess the value of selective serotonin reuptake inhibitors (SSRIs) as there are few trials in neuropathic pain. The Cochrane Review Authors also found that there was insufficient high quality evidence for them to draw any conclusions about St John's Wort, venlafaxine and L-tryptophan.

 
Antidepressant drugs such as amitriptyline are effective against a variety of neuropathic pains.

Neuropathic pains result when injury or disease causes damage to the nervous system. These pains can last for months or years after any injury has healed. The damage may be in peripheral nerves that run through the body and limbs, or within the central nervous system in the spine or brain. Patients with this form of pain are frequently given antidepressant drugs, and researchers who have assessed the findings of 50 trials conducted around the world conclude that there is good evidence that at least some of them work well.

The most convincing evidence was for amitriptyline in doses up to 150mg per day, which achieved at least moderate pain relief. It was difficult to assess the value of selective serotonin reuptake inhibitors (SSRIs) as there are few trials in neuropathic pain. The Cochrane Review Authors also found that there was insufficient high quality evidence for them to draw any conclusions about St John's Wort, venlafaxine and L-tryptophan.

"The clinical impression is that antidepressants are effective and this review confirms this belief," said lead author Tiina Saarto who works in Helsinki University Central Hospital, Helsinki, Finland. "If the drug is going to be affective, it normally starts to reduce pain within a few days of starting to take it."

Antidepressants had most effect treating diabetic neuropathy and post-herpetic neuralglia. There was limited evidence that they could also help people with central pain, atypical facial pain and pain after breast cancer treatment. There was a lack of evidence that they helped people with HIV-related neuropathic pain or 'burning mouth syndrome'.
 

- Review Title: Saarto et al: Antidepressants for neuropathic pain. The Cochrane Database of Systematic Reviews 2005 Issue 3
 

www.interscience.wiley.com

 
Subscribe to Depression Newsletter
E-mail Address:

 

Cochrane reviews are based on the best available information about healthcare interventions. They explore the evidence for and against the effectiveness and appropriateness of treatments (medications, surgery, education, etc) in specific circumstances.

The complete reviews are published in The Cochrane Library which is available by subscription, either on CDROM or via the Internet. You should be able to browse the Cochrane Library at your nearest medical library if you don't have your own subscription.

The Cochrane Library is published four times a year. Each issue contains all existing reviews plus an increasingly wider range of new and updated reviews. It is published and distributed by Wiley InterScience and is also distributed by a number of other Distribution Partners. It is not available for sale from Cochrane Centres.


Related Depression News

New brain-chemistry differences found in depressed women
Stereotypical self-image interferes with depression treatment
Exaggerated inflammatory response to psychological stress seen in major depression
Ever-happy mice may hold key to new treatment of depression
Treating depression may raise anxiety levels
Depressed singles receive greater psychological benefits from getting married
STAR*D Trial: Third antidepressant medication might help in treatment-resistant depression
Residual Depressive Cognitions could Predict Relapse of Depressive Illness
Link Between Depression and Heart Disease
Social factors not hormones cause post-natal depression


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us